Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Blood (2024) 144 (1): 74–83.

https://doi.org/10.1182/blood.2024023938

Published: 2024

Includes: Supplemental data

Journal Articles

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Blood (2023) 142 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2023-180355

Published: 2023

Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blood (2023) 142 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2023-178473

Published: 2023

Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Blood (2022) 140 (Supplement 1): 8971–8972.

https://doi.org/10.1182/blood-2022-168568

Published: 2022

Journal Articles

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Shaun Fleming, John Reynolds, Ashish Bajel, Nicola Venn, John Kwan, John Moore, David T Yeung, Nalini Pati, Michael F. Leahy, Joanna Nkyekyer, Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew H. Wei, Matthew Greenwood

Blood (2021) 138 (Supplement 1): 1234.

https://doi.org/10.1182/blood-2021-151826

Published: 2021

Journal Articles

Targeted Next Generation Sequencing Reveals a Third Breakpoint Cluster Region and New Partner Genes in the KMT2A Recombinome

Claus Meyer, Patrizia Larghero, Bruno Lopes, Aurélie Caye-Eude, Hélène Cavé, Marius Külp, Matthew James Smith, Rosemary Sutton, Nicola Venn, Karin Nebral, Susanne Kubetzko, Beat Schaefer, Grazia Fazio, Giovanni Cazzaniga, Mariana Emerenciano, Rolf Marschalek

Blood (2021) 138 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2021-146172

Published: 2021

Journal Articles

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

Laura N Eadie, BSc, PhD, Jacqueline Rehn, MSc(BioTech), Susan L Heatley, PhD MD, Barbara J McClure, BSc,PhD, Caitlin Schutz Schutz, BSc (Hons), James Breen, BSc,PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Rosemary Sutton, BSc MSc PhD, Deborah L White, PhDFFSc(RCPA)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-138995

Published: 2020

Journal Articles

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-139376

Published: 2020

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Shaun Fleming, MBBS,, Nicola Venn, BSc, John Reynolds, PhD, Uyen Nguyen, John Kwan, MBBS,FRACP,FRCPA, John Moore, MDFRACP,FRCPA, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Matthew Greenwood, MBBS, FRACP, FRCPA, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Ashish Bajel, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Rosemary Sutton, BSc MSc PhD

Blood (2019) 134 (Supplement_1): 1300.

https://doi.org/10.1182/blood-2019-132048

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

Alexander A Morley, MD, Sue Latham, BSc, Elizabeth Hughes, BSc, Bradley Budgen, BSc, Matthew Greenwood, FRACP, FRCPA, Kenneth F Bradstock, Luciano Dalla-Pozza, MBBS FRACP, Tamara Law, PhD, Louise Doculara, BSc, Nicola Venn, BSc, Rosemary Sutton, PhD

Blood (2018) 132 (Supplement 1): 2831.

https://doi.org/10.1182/blood-2018-99-110123

Published: 2018

Journal Articles

MLL-USP2 : An Underestimated New Entity of MLL -Rearranged Leukemia Identified By NGS Analysis

Claus Meyer, PhD, Bruno Lopes, PhD, Aurélie Caye-Eude, PharmD, Hélène Cavé, PharmD, PhD, Chloé Arfeuille, PhD, Rosemary Sutton, PhD, Nicola Venn, BSc, Patrizia Larghero, PhD, Seung Hwan Oh, MD, Grigory Tsaur, MD PhD, Marketa Zaliova, Jan Zuna, Vesa Juvonen, PhD, Renate Panzer-Grümayer, MD, Grazia Fazio, PhD, Giovanni Cazzaniga, PhD, Mariana Emerenciano, PhD, Rolf Marschalek, PhD

Blood (2018) 132 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2018-99-112594

Published: 2018

Journal Articles

Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL -Rearranged Acute Myeloid Leukemia

Sadia Afrin, PhD, Christine RC Zhang, PhD, Claus Meyer, PhD, Mellissa Maybury, PhD, Thy Pham, BAppSc (Hons), Nicola Venn, BSc, Toby N Trahair, MBBS FRACP PhD, Rosemary Sutton, PhD, Rolf Marschalek, PhD, Lynn Fink, PhD, Andrew S. Moore, MBBS, FRACP, PhD

Blood (2018) 132 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2018-99-117761

Published: 2018

Journal Articles

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

Marion K Mateos, MBBS FRACP, Toby N Trahair, MBBS FRACP PhD, Chelsea Mayoh, BSc, Pasquale M Barbaro, MBBS FRACP FRCPA, Carly George, MBBS, FRACP, Rosemary Sutton, PhD, Tamas Revesz, MDPhDD.Sc FRACP FRCPA, Draga Barbaric, MBBS FRACP, Jodie Giles, Frank Alvaro, FRACP, MBBS, Francoise Marie Mechinaud, MD FRACP, Daniel R Catchpoole, PhD BSc, Rishi Sury Kotecha, MBBChir, MRCP, FRACP, PhD, Michael CJ Quinn, BSc MSc PhD, Georgia Chenevix-Trench, BSc PhD, Stuart MacGregor, BSc MSc PhD, Luciano Dalla-Pozza, MBBS FRACP, Glenn M Marshall, MBBS, MD FRACP

Blood (2017) 130 (Supplement 1): 2102.

https://doi.org/10.1182/blood.V130.Suppl_1.2102.2102

Published: 2017

Journal Articles

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorkova, Marketa Zaliova, Nicola C. Venn, Kirsten Bleckmann, Marie Trkova, Eliska Potuckova, Martina Vaskova, Jana Linhartova, Katerina Machova Polakova, Eva Fronkova, Walter Muskovic, Jodie E. Giles, Peter J. Shaw, Gunnar Cario, Rosemary Sutton, Jan Stary, Jan Trka, Jan Zuna

Blood (2017) 129 (20): 2771–2781.

https://doi.org/10.1182/blood-2016-11-749978

Published: 2017

Includes: Supplemental data

Journal Articles

Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E)

Sadia Afrin, BSc (Hons) MSc, Claus Meyer, PhD, Caedyn L. Stinson, BSc, Thy Pham, BAppSc (Hons), Timothy J.C. Bruxner, PhD, Nicola C. Venn, BSc (Hons), Toby N. Trahair, MBBS FRACP PhD, Rosemary Sutton, BSc PhD, Rolf Marschalek, PhD, Lynn Fink, PhD, Andrew S. Moore, MBBS FRACP PhD

Blood (2016) 128 (22): 2908.

https://doi.org/10.1182/blood.V128.22.2908.2908

Published: 2016

Journal Articles

Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL

Rosemary Sutton, PhD, Tamara Law, BSc (Hons), Nicola C Venn, BSc (Hons), Carol Wadham, PhD, Emily VA Mould, PhD, Murray D Norris, PhD, Rishi S Kotecha, MB ChB FRACP PhD, Rolf Marschalek, PhD, Claus Meyer, PhD, Luciano Dalla-Pozza, MB BS FRACP, Glenn M Marshall, MBBS, MD FRACP, Richard B Lock, PhD, Toby N. Trahair, MBBS FRACP PhD

Blood (2016) 128 (22): 1740.

https://doi.org/10.1182/blood.V128.22.1740.1740

Published: 2016

Journal Articles

Clinical Predictors of Venous Thromboembolism during Therapy for Childhood Acute Lymphoblastic Leukemia

Marion K Mateos, MBBS FRACP, Toby N. Trahair, MBBS FRACP PhD, Chelsea Mayoh, BSc, Pasquale M Barbaro, MBBS FRACP FRCPA, Rosemary Sutton, BSc PhD, Tamas Revesz, MD PhDD.Sc FRACP FRCPA, Draga Barbaric, MBBS FRACP, Jodie Giles, Frank Alvaro, MBBS, FRACP, Francoise Mechinaud, MD FRACP, Daniel Catchpoole, BSc PhDFFSc(RCPA), Rishi S Kotecha, MB ChB FRACP PhD, Luciano Dalla-Pozza, MB BS FRACP, Glenn M Marshall, MBBS, MD FRACP

Blood (2016) 128 (22): 1182.

https://doi.org/10.1182/blood.V128.22.1182.1182

Published: 2016

NARROW

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Targeted Next Generation Sequencing Reveals a Third Breakpoint Cluster Region and New Partner Genes in the KMT2A Recombinome

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

MLL-USP2 : An Underestimated New Entity of MLL -Rearranged Leukemia Identified By NGS Analysis

Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL -Rearranged Acute Myeloid Leukemia

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E)

Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL

Clinical Predictors of Venous Thromboembolism during Therapy for Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only